BR112015023429A8 - anticorpos pac1 humanos - Google Patents

anticorpos pac1 humanos

Info

Publication number
BR112015023429A8
BR112015023429A8 BR112015023429A BR112015023429A BR112015023429A8 BR 112015023429 A8 BR112015023429 A8 BR 112015023429A8 BR 112015023429 A BR112015023429 A BR 112015023429A BR 112015023429 A BR112015023429 A BR 112015023429A BR 112015023429 A8 BR112015023429 A8 BR 112015023429A8
Authority
BR
Brazil
Prior art keywords
antibodies
pac1
human pac1
binding fragments
headache
Prior art date
Application number
BR112015023429A
Other languages
English (en)
Other versions
BR112015023429B1 (pt
BR112015023429A2 (pt
Inventor
Eva Hamburger Agnes
Xu Cen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112015023429A2 publication Critical patent/BR112015023429A2/pt
Publication of BR112015023429A8 publication Critical patent/BR112015023429A8/pt
Publication of BR112015023429B1 publication Critical patent/BR112015023429B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

resumo anticorpos pac1 humanos anticorpos e fragmentos de ligação de antígeno dos mesmos que se ligam a pac1 humana são fornecidos. ácidos nucleicos que codificam os anticorpos e fragmentos de ligação de antígeno dos mesmos, vetores, e células que codificam os mesmos também são fornecidos. os anticorpos e fragmentos de ligação de antígeno dos mesmos podem inibir a ligação de pac1 a pacap, e são úteis em vários distúrbios relacionados com pac1, incluindo o tratamento e/ou prevenção de distúrbios de dor de cabeça, incluindo enxaqueca e dor de cabeça em salvas.
BR112015023429-1A 2013-03-15 2014-03-14 Anticorpo isolado ou fragmento de ligação de antígeno do mesmo,composição farmacêutica e uso do referido anticorpo ou fragmento de ligação de antígeno do mesmo BR112015023429B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792678P 2013-03-15 2013-03-15
US61/792,678 2013-03-15
PCT/US2014/029128 WO2014144632A2 (en) 2013-03-15 2014-03-14 Human pac1 antibodies

Publications (3)

Publication Number Publication Date
BR112015023429A2 BR112015023429A2 (pt) 2017-11-28
BR112015023429A8 true BR112015023429A8 (pt) 2018-01-23
BR112015023429B1 BR112015023429B1 (pt) 2023-08-15

Family

ID=

Also Published As

Publication number Publication date
US9676851B2 (en) 2017-06-13
AU2019204980A1 (en) 2019-08-01
AR095611A1 (es) 2015-10-28
US10472417B2 (en) 2019-11-12
TWI636064B (zh) 2018-09-21
TW201522375A (zh) 2015-06-16
JP6443870B2 (ja) 2018-12-26
AU2014228924A9 (en) 2016-06-16
IL262804A (en) 2018-12-31
US10793631B2 (en) 2020-10-06
US20160039939A1 (en) 2016-02-11
EP3683237A1 (en) 2020-07-22
KR20150128982A (ko) 2015-11-18
UY35483A (es) 2014-08-29
JP2016514458A (ja) 2016-05-23
US20200172614A1 (en) 2020-06-04
JP2019024501A (ja) 2019-02-21
TW201902931A (zh) 2019-01-16
JP6283408B2 (ja) 2018-02-21
AP2015008732A0 (en) 2015-09-30
JP2018076373A (ja) 2018-05-17
CN105143267A (zh) 2015-12-09
AU2014228924B2 (en) 2019-04-18
WO2014144632A8 (en) 2015-12-30
WO2014144632A2 (en) 2014-09-18
PE20151923A1 (es) 2016-01-14
EA032830B1 (ru) 2019-07-31
MA38478A1 (fr) 2017-11-30
US9365653B2 (en) 2016-06-14
US10053507B2 (en) 2018-08-21
US20180094055A1 (en) 2018-04-05
ES2770976T3 (es) 2020-07-06
US9822178B2 (en) 2017-11-21
US10294298B2 (en) 2019-05-21
CR20150575A (es) 2016-01-06
AU2014228924A1 (en) 2015-10-01
BR112015023429A2 (pt) 2017-11-28
US20160251432A1 (en) 2016-09-01
EP2970470A2 (en) 2016-01-20
CL2015002750A1 (es) 2016-03-04
US20170247451A1 (en) 2017-08-31
EA201591791A1 (ru) 2016-03-31
IL241382A0 (en) 2015-11-30
US20180362645A1 (en) 2018-12-20
CA2906737C (en) 2023-08-15
WO2014144632A3 (en) 2014-11-20
CN105143267B (zh) 2020-06-26
US20150010560A1 (en) 2015-01-08
TN2015000425A1 (en) 2017-01-03
PH12015502126A1 (en) 2016-01-25
HK1218554A1 (zh) 2017-02-24
KR102215405B1 (ko) 2021-02-10
HK1219958A1 (zh) 2017-04-21
SG11201507416WA (en) 2015-10-29
MX2015013181A (es) 2015-12-11
EP2970470B1 (en) 2019-12-04
CA2906737A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
UY35483A (es) Anticuerpos pac1 humanos
MX2022012089A (es) Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos.
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CY1122978T1 (el) Αντισωματα εναντι-vla-4
WO2016196975A8 (en) Neutralizing antibodies to hiv-1 env and their use
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112017025529A2 (pt) agentes de ligação ao tigit e usos destes
BR112017013385A2 (pt) anticorpos para tigit
EA201891366A1 (ru) Гуманизированные антитела против cd73
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
EA201400875A1 (ru) Антитела к cd47 и способы их применения
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
PH12016500275B1 (en) Antibodies
PH12019500571A1 (en) Anti-pd-1 antibodies
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
BR112014019611A2 (pt) agentes de ligação mica
EA201892774A1 (ru) Антитела
MX2022015197A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
EA201400447A1 (ru) АНТИТЕЛА К CD1d
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS